Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 10/20 | 0.49 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 3/20 | 0.41 |
| ▸ | PYGM | P11217 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674154 | 1.00 | PYGB (0.49) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL29484208 | 1.00 | PYGB (0.49) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL15284881 | 1.00 | PYGB (0.49) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL29406981 | 1.00 | PYGB (0.49) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL31598843 | 0.83 | PYGB (0.43) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL30569120 | 0.83 | PYGB (0.43) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL11505360 | 0.83 | PYGB (0.52) | PYGBPYGLPYGM | |
| SCHEMBL9221292 | 0.81 | PYGB (0.48) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL10357870 | 0.81 | PYGB (0.51) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL30381206 | 0.80 | PYGB (0.43) | PYGBPYGLPYGMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997917-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术有限公司 | 2020-04-10 | — | — | CN | claimed |
| CN-110945132-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术有限公司 | 2020-03-31 | — | — | CN | claimed |
| WO-2026087607-A1 | SUBCUTANEOUS ADMINISTRATION OF SIALYLATED HUMAN FACTOR H PROTEIN | eleva GmbH (DE) | 2026-04-30 | — | — | WO | disclosed |
| EP-4555078-A1 | NEW FUCOSYLTRANSFERASE FOR IN VIVO SYNTHESIS OF COMPLEX FUCOSYLATED HUMAN MILK OLIGOSACCHARIDES | DSM IP Assets B.V. (NL) | 2025-05-21 | — | — | EP | disclosed |
| EP-3801531-B1 | LOW GLYCEMIC GUMMY COMPOSITION AND METHODS OF MAKING AND USING THEREOF | SEATTLE GUMMY COMPANY (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2024013398-A1 | NEW FUCOSYLTRANSFERASE FOR IN VIVO SYNTHESIS OF COMPLEX FUCOSYLATED HUMAN MILK OLIGOSACCHARIDES | DSM IP ASSETS B.V. (NL) | 2024-01-18 | — | — | WO | disclosed |
| US-11661471-B2 | Urethane-crosslinked biodegradable elastomers | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-30 | — | — | US | disclosed |
| EP-4114949-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN (TTR) | Alnylam Pharmaceuticals, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220213252-A1 | URETHANE-CROSSLINKED BIODEGRADABLE ELASTOMERS | BIOCANT-CENTER OF INNOVATION AND BIOTECHNOLOGY (PT) | 2022-07-07 | — | — | US | disclosed |
| EP-3966246-A1 | MODULATING ANTIBODY EFFECTOR FUNCTIONS | Amgen, Inc (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11254781-B2 | Urethane-crosslinked biodegradable elastomers | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-02-22 | — | — | US | disclosed |
| CN-106939292-B | Lung-clearing haze-removing camel lactic acid beverage and preparation method and application thereof | 天山牧歌投资管理有限公司 | 2021-03-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254781-B2 | Urethane-crosslinked biodegradable elastomers | PUF60, XRCC5, XRCC6 | PYGB 2454/4885OGA 123/4885PYGL 2593/4885 |
| US-11661471-B2 | Urethane-crosslinked biodegradable elastomers | PUF60, XRCC5, XRCC6 | PYGB 2454/4885OGA 123/4885PYGL 2593/4885 |
| US-20220213252-A1 | URETHANE-CROSSLINKED BIODEGRADABLE ELASTOMERS | PUF60, XRCC5, XRCC6 | PYGB 2454/4885OGA 123/4885PYGL 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.